Oxford Biomedica PLC 2022 AR2
The report highlights Oxford Biomedica's significant progress in 2022, including the establishment of Oxford Biomedica Solutions in the US, expanding its capabilities into the adeno-associated virus (AAV) market. The Group achieved total revenues of £140.0 million and expanded its client base to 18 clients across multiple viral vector types. Additionally, the company completed a sale and leaseback of its Windrush Court facility for £60 million and was included in the FTSE4Good index. On the environmental front, the Group established a roadmap to achieve net zero greenhouse gas emissions across all operations by 2040.
Company: Oxford Biomedica PLC
Sector: Health Care
Country: United Kingdom
Year: 2022
Type: AR2
Pages: 186
Oxford Biomedica PLC
Annual Report And Accounts
The report highlights Oxford Biomedica's significant progress in 2022, including the establishment of Oxford Biomedica Solutions in the US, expanding its capabilities into the adeno-associated virus (AAV) market. The Group achieved total revenues of £140.0 million and expanded its client base to 18 clients across multiple viral vector types. Additionally, the company completed a sale and leaseback of its Windrush Court facility for £60 million and was included in the FTSE4Good index. On the environmental front, the Group established a roadmap to achieve net zero greenhouse gas emissions across all operations by 2040.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Women on Board
Women in Management
Net Zero Target
Employees